Larimar Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LRMR research report →
Companywww.larimartx.com
Larimar Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease.
- CEO
- Carole S. Ben-Maimon
- IPO
- 2014
- Employees
- 65
- HQ
- Bala Cynwyd, PA, US
Price Chart
Valuation
- Market Cap
- $289.25M
- P/E
- -1.73
- P/S
- 0.00
- P/B
- 1.82
- EV/EBITDA
- -0.68
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -134.14%
- ROIC
- -106.56%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-165,673,000 · -105.54%
- EPS
- $-2.27 · -71.97%
- Op Income
- $-172,497,000
- FCF YoY
- -58.95%
Performance & Tape
- 52W High
- $6.42
- 52W Low
- $1.80
- 50D MA
- $4.48
- 200D MA
- $4.02
- Beta
- 0.91
- Avg Volume
- 4.51M
Get TickerSpark's AI analysis on LRMR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 27, 26 | Flynn James E | buy | 1,084,012 |
| Feb 27, 26 | Flynn James E | buy | 1,084,010 |
| Feb 27, 26 | Flynn James E | buy | 831,978 |
| Feb 27, 26 | Flynn James E | buy | 2,000,000 |
| Feb 27, 26 | Hamilton Thomas Edward | buy | 100,000 |
| Feb 27, 26 | THOMAS FRANK E | buy | 5,000 |
| Feb 27, 26 | SHERMAN JEFFREY W | buy | 5,000 |
| Jan 26, 26 | Shankar Gopi | other | 153,822 |
| Jan 26, 26 | Shankar Gopi | other | 25,637 |
| Jan 26, 26 | Clayton Russell | other | 153,822 |
Our LRMR Coverage
We haven't published any research on LRMR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LRMR Report →